References
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.
Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP . Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol 2004; 75: 22–33.
Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–3389.
Johnston JB, Paul JT, Neufeld NJ, Haney N, Kropp DM, Hu X et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leukemia Lymphoma 2004; 45: 2017–2027.
Moshynska O, Sankaran K, Pahwa P, Saxena A . Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst 2004; 96: 673–682.
Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M et al. Somatically mutated Ig V(H)3–21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99: 2262–2264.
Acknowledgements
We are grateful to Drs Lars Klareskog and Leonid Padyukov and to the EIRA group for help with the collection of the normal control material. This study was supported by grants from the Swedish Cancer Society, Lion's Cancer Research Foundation, Uppsala and the research foundation of the Department of Oncology at Uppsala University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tobin, G., Skogsberg, Å., Thunberg, U. et al. Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia. Leukemia 19, 871–873 (2005). https://doi.org/10.1038/sj.leu.2403715
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403715
- Springer Nature Limited
This article is cited by
-
MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL
BMC Cancer (2015)
-
Genetic alterations in chronic lymphocytic leukaemia
Clinical and Translational Oncology (2009)
-
The BCL-2 promoter (−938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia
Leukemia (2008)